AstraZeneca and Bristol-Myers Squibb Merger Rumors Denied
Alina Collins
A senior source has formally denied any merger discussions between AstraZeneca and Bristol Myers Squibb, stating the two companies never held any talks. The rumor had earlier pushed AstraZeneca's stock down roughly 9%; with the deal ruled out, its shares should revert to fundamentals.
What exactly happened?
Reuters, citing a senior insider, reported that "there are no discussions" between AstraZeneca and Bristol Myers Squibb — the merger rumor is officially dead.
The source, speaking anonymously, was blunt: "There is no deal. There never was a deal to discuss."
The Financial Times first reported contact between the two pharma giants; Reuters later cited sources saying there had been preliminary contact.
How big would this deal have been?
Had a merger gone through, the combined entity would have approached a $400 billion market cap — one of the largest pharma deals ever.
This means → the rumor rattled markets precisely because a deal of that scale could reshape the global pharma landscape.
How did the market react?
AstraZeneca's stock fell roughly 9% on the rumor, while Bristol Myers Squibb shares stayed relatively flat.
In plain terms = the market feared AstraZeneca would overpay as the acquirer, so it sold the stock first; Bristol Myers Squibb, as the potential target, was largely unscathed.
With the merger now firmly ruled out, AstraZeneca's share price should revert to fundamental drivers, and the rumor-driven sell-off pressure is likely to ease.
Content is for reference only, not financial advice.